點(diǎn)擊圖片查看大圖
PF06463922勞拉替尼價(jià)格咨詢(xún)武漢新百川醫(yī)藥
PF06463922勞拉替尼生產(chǎn)廠家就找武漢新百川醫(yī)藥
PF06463922勞拉替尼供應(yīng)商武漢新百川醫(yī)藥更專(zhuān)業(yè)
PF06463922勞拉替尼哪里有？武漢新百川醫(yī)藥有現(xiàn)貨
PF06463922勞拉替尼哪家工廠生產(chǎn)？武漢新百川醫(yī)藥專(zhuān)業(yè)生產(chǎn)
PF06463922勞拉替尼現(xiàn)貨，PF06463922純度,PF06463922含量,PF06463922價(jià)格，
PF06463922勞拉替尼生產(chǎn)廠家就找武漢新百川醫(yī)藥
PF06463922勞拉替尼供應(yīng)商武漢新百川醫(yī)藥更專(zhuān)業(yè)
PF06463922勞拉替尼哪里有？武漢新百川醫(yī)藥有現(xiàn)貨
PF06463922勞拉替尼哪家工廠生產(chǎn)？武漢新百川醫(yī)藥專(zhuān)業(yè)生產(chǎn)
PF06463922勞拉替尼現(xiàn)貨，PF06463922純度,PF06463922含量,PF06463922價(jià)格，
PF06463922勞拉替尼
CAS NO. 1454846-35-5
英文品名? PF-06463922
分子式 C21H19FN6O2
分子量 406.15
規(guī)格/純度 99%
供應(yīng)能力 can supply g scale
別名? PF 06463922;PF06463922
產(chǎn)品簡(jiǎn)述? PF-06463922 is a novel, orally available, CNS-penetrant, ATP-competitive inhibitor of ALK/ROS1 with Ki of <0.02 nM, <0.07 nM, and 0.7 nM for ROS1, ALK (WT), and ALK (L1196M), respectively.
詳細(xì)說(shuō)明 PF-06463922 demonstrates significant cell activity against ALK and a large set of ALK clinical mutations with IC50 ranging from 0.2 nM-77 nM. PF-06463922 exhibited subnanomolar cellular potency against oncogenic ROS1 fusions and inhibited the crizotinib-refractory ROS1(G2032R) mutation and the ROS1(G2026M) gatekeeper mutation. Compared with crizotinib and the second-generation ALK/ROS1 inhibitors ceritinib and alectinib, PF-06463922 showed significantly improved inhibitory activity against ROS1 kinase. in vivo: PF-06463922 showed marked antitumor activity in tumor models expressing FIG-ROS1, CD74-ROS1, and the CD74-ROS1(G2032R) mutation. Furthermore, PF-06463922 demonstrated antitumor activity in a genetically engineered mouse model of FIG-ROS1 glioblastoma.
詳細(xì)說(shuō)明 PF-06463922 demonstrates significant cell activity against ALK and a large set of ALK clinical mutations with IC50 ranging from 0.2 nM-77 nM. PF-06463922 exhibited subnanomolar cellular potency against oncogenic ROS1 fusions and inhibited the crizotinib-refractory ROS1(G2032R) mutation and the ROS1(G2026M) gatekeeper mutation. Compared with crizotinib and the second-generation ALK/ROS1 inhibitors ceritinib and alectinib, PF-06463922 showed significantly improved inhibitory activity against ROS1 kinase. in vivo: PF-06463922 showed marked antitumor activity in tumor models expressing FIG-ROS1, CD74-ROS1, and the CD74-ROS1(G2032R) mutation. Furthermore, PF-06463922 demonstrated antitumor activity in a genetically engineered mouse model of FIG-ROS1 glioblastoma.
新百川醫(yī)藥替尼類(lèi)新型抗腫瘤小分子抑制劑：馬來(lái)酸，，，，蘋(píng)果酸，阿西替尼，托法替尼，，魯索替尼，巴瑞克替尼，色瑞替尼，，多韋替尼，司美替尼，達(dá)克替尼（Dacomitinib，PF299804），PF0643922;勞拉替尼，布格替尼Brigatinib，，替沃扎尼475108-18-0
歡迎來(lái)電咨詢(xún)唐經(jīng)理 18607136887|027-50476178|QQ644526144
免責(zé)聲明：（1）以上所展示的信息由企業(yè)自行提供，內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由發(fā)布企業(yè)負(fù)責(zé)，環(huán)球塑化網(wǎng)對(duì)此不承擔(dān)任何保證責(zé)任。我們?cè)瓌t上建議您優(yōu)先選擇“塑企通”會(huì)員合作! （2）同時(shí)我們鄭重提醒各位買(mǎi)/賣(mài)家，交易前請(qǐng)?jiān)敿?xì)核實(shí)對(duì)方身份，切勿隨意打款或發(fā)貨，謹(jǐn)防上當(dāng)受騙。如發(fā)現(xiàn)虛假信息，請(qǐng)向環(huán)球塑化網(wǎng)舉報(bào)。
簡(jiǎn)繁切換